Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2016 - 2023)
Myriad Genetics has reported Non-Current Deferred Tax Liability over the past 10 years, most recently at $2.7 million for Q3 2023.
- Quarterly Non-Current Deferred Tax Liability fell 74.29% to $2.7 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Sep 2023, down 74.29% year-over-year, with the annual reading at $3.5 million for FY2022, 97.28% down from the prior year.
- Non-Current Deferred Tax Liability was $2.7 million for Q3 2023 at Myriad Genetics, down from $3.7 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $128.6 million in Q4 2021 and troughed at $2.7 million in Q3 2023.
- The 5-year median for Non-Current Deferred Tax Liability is $58.2 million (2021), against an average of $47.2 million.
- Year-over-year, Non-Current Deferred Tax Liability soared 118.8% in 2021 and then crashed 97.28% in 2022.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $75.5 million in 2019, then decreased by 5.56% to $71.3 million in 2020, then skyrocketed by 80.36% to $128.6 million in 2021, then crashed by 97.28% to $3.5 million in 2022, then decreased by 22.86% to $2.7 million in 2023.
- Per Business Quant, the three most recent readings for MYGN's Non-Current Deferred Tax Liability are $2.7 million (Q3 2023), $3.7 million (Q2 2023), and $4.1 million (Q1 2023).